Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News JOHNSON & JOHNSON JNJ

Healthcare
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including... see more

Recent & Breaking News (NYSE:JNJ)

Johnson & Johnson to Acquire V-Wave

Business Wire August 20, 2024

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE(TM) (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer

PR Newswire August 20, 2024

Groundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of Medicine

PR Newswire August 7, 2024

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible

PR Newswire July 30, 2024

Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference

Business Wire July 29, 2024

Courts, Congress Likely to Stand in Way of J&J's Third Texas Two-Step Plan

Business Wire July 26, 2024

FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan

Business Wire July 26, 2024

Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Business Wire July 23, 2024

Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J's Latest Bankruptcy Plan

Business Wire July 22, 2024

Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression

PR Newswire July 22, 2024

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024

Business Wire July 17, 2024

Johnson & Johnson reports Q2 2024 results

Business Wire July 17, 2024

NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors

GlobeNewswire July 15, 2024

Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26

Business Wire July 11, 2024

Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Canada NewsWire July 3, 2024

CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study

PR Newswire July 2, 2024

Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients

PR Newswire June 28, 2024

Lawyers for Johnson & Johnson's Ovarian Cancer Victims React to SCOTUS Decision in Purdue

Business Wire June 27, 2024

Johnson & Johnson Completes Acquisition of Proteologix, Inc.

Business Wire June 21, 2024

Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease

PR Newswire June 20, 2024